Icagen Inc. (ICGN) announced that it has initiated a proof-of-concept study of ICA-105665 in patients with photosensitive epilepsy. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been validated by both genetic and physiologic evidence as playing an important role in certain conditions characterized by abnormal neuroexcitability, such as seizures, and potentially also chronic pain disorders.
The photosensitive epilepsy study was designed with international experts including members of the Epilepsy Study Consortium and would be conducted at up to four clinical research centers in the United States with specialized expertise in the conduct of this study. The study is expected to be completed by mid-2010, the company added.
For comments and feedback: editorial@rttnews.com